SMXXF News Alert Summit Corporation (SMXXF) 2.3000 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Summit Corporation (SMXXF) 2.3000 $SMXXF

Plague - Pipeline Review, H1 2014
M2 - Wed Jul 30, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xgdb3j/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Plague - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Plague and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Takeda Pharmaceutical - Summit Corporation - Mucosis - iBio - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/xg...e_pipeline

Dementia Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pmw68m/dementia) has announced the addition of the "Dementia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Sylentis S.A. - FORUM Pharmaceuticals Inc. - Ildong Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - WhanIn Pharmaceutical Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Summit Corporation plc - Oryzon Genomics S.A. - Intellect Neurosciences, Inc. - Intra-Cellular Therapies, Inc. - Tautatis Incorporated - Pacific Northwest Biotechnology, LLC - Otsuka Holdings Co., Ltd. - Chase Pharmaceuticals Corporation - Echo Pharmaceuticals B.V. - Chronos Therapeutics Limited - Alector LLC - ImStar Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/pmw68m/dementia

USHCC Announces 2014 Legislative Summit Featured Speakers
GlobeNewswire - Mon Mar 24, 9:07PM CDT
The United States Hispanic Chamber of Commerce (USHCC) is proud to announce the participation of an all-star lineup during its 2014 Legislative Summit, which will take place at the Capital Hilton from March 25 - 27. The Legislative Summit is the USHCC's premier advocacy event where the Hispanic business community hears from national political leaders, have access to high-level networking opportunities, engage in policy workshops, participate in procurement matchmaking sessions with federal agencies, and have the chance to meet with Congressional representatives on Capitol Hill.

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Plague - Latest Pipeline Review Report
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/9r77ph/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H2 2013" report to their offering. 'Plague - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Plague, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plague. Scope - A snapshot of the global therapeutic scenario for Plague. - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Plague pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Plague - Companies Involved in Therapeutics Development - Takeda Pharmaceutical Company Limited - Summit Corporation plc - Mucosis B.V. - iBio, Inc. - Cellceutix Corporation Drug Profiles - rF1V Vaccine - Flagellin/F1/V Vaccine - PMX-30016 - SMT-15000 - Subunit Vaccine For Plague - Plague Vaccine - Yersinia Pestis Vaccine - Subunit Vaccine For Anthrax-Plague Combination - Yersinia Pestis Vaccine - Yersinia Pestis Vaccine - tPA-V DNA Vaccine - Small Molecule to Inhibit YoPH for Plague For more information visit http://www.researchandmarkets.com/research/9r...e_pipeline

Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Tuberculosis - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Tuberculosis
M2 - Mon Sep 02, 11:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bnt58v/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Tuberculosis. - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tuberculosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AVI BioPharma Inc. - Achillion Pharmaceuticals, Inc. - Advinus Therapeutics Pvt. Ltd. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BT PHARMA - Canopus BioPharma Incorporated - Chimerix, Inc. - Crucell N.V. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline Inc. - GlaxoSmithKline plc - Hollis-Eden Pharmaceuticals, Inc. - ISA Pharmaceuticals B.V. - Immune Network Research Ltd. - ImmunoBiology Limited - ImmunoVaccine Technologies Inc. - Johnson & Johnson - Lipotek Pty Ltd - Medisyn Technologies, Inc. - MicuRx Pharmaceuticals, Inc. - Mondobiotech Holding AG - NeED Pharma s.r.l. - Okairos - Pharminox Limited - Piramal Healthcare Limited - Pt. Bio Farma - Recipharm AB - Sanofi-Aventis - Sequella, Inc. - Snowdon Inc. - Statens Serum Institut - Summit Corporation plc - TVAX Biomedical, LLC - Transgene SA - Vakzine Projekt Management GmbH - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/bn...berculosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Ebola Viral Infections - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g94m3t/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola Viral Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola Viral Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola Viral Infections. Scope - A snapshot of the global therapeutic scenario for Ebola Viral Infections. - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola Viral Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Tekmira Pharmaceuticals Corp. Medicago Inc. CombinatoRx, Incorporated Summit Corporation plc Functional Genetics, Inc. Evolva SA Vaxart, Inc. Prosetta Corporation For more information visit http://www.researchandmarkets.com/research/g9...bola_viral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Metastatic Melanoma - Pipeline Review, H2 2012
M2 - Mon Aug 12, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mttj8/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H2 2012" report to their offering. This data provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Melanoma. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Metastatic Melanoma - A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Coverage of products based on various stages of development ranging from discovery till registration stages - A feature on pipeline projects on the basis of monotherapy and combined therapeutics - Coverage of the Metastatic Melanoma pipeline on the basis of route of administration and molecule type - Key discontinued pipeline projects - Latest news and deals relating to the products Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Metastatic Melanoma Overview Therapeutics Development An Overview of Pipeline Products for Metastatic Melanoma Companies Involved in Metastatic Melanoma Therapeutics Development Metastatic Melanoma - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - 3SBio Inc - AVAX Technologies - Abbott Laboratories - Antigenics - BioAlliance Pharma - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics - Eli Lilly and Company - F. Hoffmann-La Roche - Genentech - GlaxoSmithKline - Hemispherx Biopharma - Incyte Corporation - Lorus Therapeutics - Millennium Pharmaceuticals - Molecular Insight Pharmaceuticals - Morphotek - Northwest Biotherapeutics - Novartis AG - Oncolytics Biotech - Ono Pharmaceutical - Osta Biotechnologies - Oxford BioMedica - Pain Therapeutics - Progen Pharmaceuticals Limited - Provectus Pharmaceuticals - Summit Corporation - Vical Incorporated - Viralytics For more information visit http://www.researchandmarkets.com/research/5mttj8/metastatic

Skin Inflammation - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cclx3v/skin_inflammation) has announced the addition of the "Skin Inflammation - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Skin Inflammation therapeutic pipeline. This report provides information on the therapeutic development for Skin Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Inflammation. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Skin Inflammation Overview Therapeutics Development An Overview of Pipeline Products for Skin Inflammation Companies Involved in Skin Inflammation Therapeutics Development Skin Inflammation - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles Skin Inflammation Therapeutics - Drug Profile Updates Skin Inflammation Therapeutics - Discontinued Products Skin Inflammation Therapeutics - Dormant Products Skin Inflammation - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned - APEIRON Biologics AG - Action Pharma A/S - Almirall, S.A - Amgen Inc - AnGes MG, Inc - AnaMar Medical AB - Anacor Pharmaceuticals, Inc - Array BioPharma Inc - Asubio Pharmaceuticals, Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - CREABILIS Therapeutics S.r.l. - Celtic Pharmaceutical Holdings L.P - Clarassance, Inc - Companies Involved in Skin Inflammation Therapeutics Development - Cutanea Life Sciences - Daiichi Sankyo Company, Ltd - Deciphera Pharmaceuticals, LLC - EMS S.A - Eisai Co., Ltd - Fougera - Galderma S.A. - GlaxoSmithKline plc - Hanall Pharmaceutical Co., Ltd - Hawthorn Pharmaceuticals, Inc - Hygeia Therapeutics, Inc - IMMD Inc. - JADO Technologies GmbH. - LEO Pharma A/S - MIKA Pharma GmbH - Maruho Co.,Ltd - MedImmune LLC - Melior Discovery, Inc. - Morphotek, Inc - Morria Biopharmaceuticals Plc - NKT Therapeutics, Inc - NicOx SA - Nippon Shinyaku Co., Ltd - Novartis AG - Nuvo Research Inc. - Oxagen Limited - Palau Pharma S.A - Paloma Pharmaceuticals, Inc - Pharis Biotec GmbH - Phytopharm Plc - ProMetic Life Sciences Inc - Provectus Pharmaceuticals, Inc - Proximagen Neuroscience plc - R-Tech Ueno, Ltd - Regeneron Pharmaceuticals, Inc - Respiratorius AB - SARcode Corporation - SWITCH Biotech LLC - Stiefel Laboratories, Inc - Summit Corporation plc - Syntrix Biosystems, Inc - Viromed Co., Ltd - Welichem Biotech Inc For more information visit http://www.researchandmarkets.com/research/cc...flammation

Dermatitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrd9dn/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dermatitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Dermatitis. - A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Dermatitis Overview Therapeutics Development An Overview of Pipeline Products for Dermatitis Dermatitis Therapeutics under Development by Companies Dermatitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Discovery and Pre-Clinical Stage Products Comparative Analysis Dermatitis Therapeutics - Products under Development by Companies Dermatitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Dermatitis Therapeutics Development Drug Profiles Dermatitis Therapeutics - Drug Profile Updates Dermatitis Therapeutics - Discontinued Products Dermatitis Therapeutics - Dormant Products Dermatitis - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned: (58) Including: - Almirall, S.A - Amgen Inc - AnGes MG - Array BioPharma Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - Daiichi Sankyo Company - Eisai Co - Galderma S.A - GlaxoSmithKline - Hanall Pharmaceutical Co - LEO Pharma A/S - MedImmune LLC - NicOx SA - Nippon Shinyaku Co - Novartis AG - Nuvo Research Inc - Phytopharm - ProMetic Life Sciences Inc - Provectus Pharmaceuticals - Proximagen Neuroscience - R-Tech Ueno - Regeneron Pharmaceuticals, Inc - Stiefel Laboratories - Summit Corporation For more information visit http://www.researchandmarkets.com/research/hrd9dn/dermatitis

Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development




Scroll down for more posts ▼

Top 10 Most Recent News Articles

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 543

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 117

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 8

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 0

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 71

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 349

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the Game-Changing Trends Transforming Food Choices

Updated Category News Views 367

Nourish Food Marketing Unveils Influential Trends for 2025 Nourish Food Marketing, a dynamic agency specializing in the food, beverage, and agriculture sector, recently unveiled its 9th annual Trend Report for 2025. This insightful report dives deep into nine major trends that will not only shape the industry but will also significantly influence consumer behavior in the...

Continue Reading
Investigation into Sezzle Inc. Over Securities Concerns

Updated Category News Views 278

Introduction to Sezzle Inc. Investigation Sezzle Inc. is currently under investigation by the Portnoy Law Firm, a notable name in securities litigation. This inquiry centers around potential securities fraud that may impact investors significantly. For those with concerns about their investments in Sezzle, it's important to understand the details surrounding this...

Continue Reading
Conagra Brands Sees Analyst Revisions Post Mixed Performance

Updated Category News Views 119

Conagra Brands Experiences Uneven Results in Latest Quarter Conagra Brands Inc (NYSE: CAG) has faced a challenging environment, reflecting a mixed performance in its latest quarterly results. The company reported earnings of 45 cents per share for the quarter, slightly surpassing expectations that predicted 44 cents per share. However, the revenue aspect did not align as...

Continue Reading
CNOOC Limited Achieves Record Oil and Gas Production Growth

Updated Category News Views 204

CNOOC Limited Achieves New Milestones in Oil and Gas Production CNOOC Limited has unveiled impressive operational results, marking a significant increase in oil and gas production. The company's dedication to strategic growth has propelled it to a record-breaking first half of 2025. As production metrics shine, CNOOC Limited (SEHK: 00883 (HKD Counter) and 80883 (RMB...

Continue Reading
Growth Prospects of the Automotive Bearing Market Ahead

Updated Category News Views 166

Understanding the Automotive Bearing Market Growth The global Automotive Bearing Market is experiencing remarkable growth, spurred by the rapid adoption of electric vehicles (EVs), advances in lightweight materials, and an increasing emphasis on fuel efficiency. Despite facing challenges like fluctuating raw material prices, supply chain issues, and counterfeit products,...

Continue Reading